Generics

Innovative Products found!

Biosimilars

Medical devices

Nutraceuticals

Filters

Pp-080 manufacturers

Filters

None products found

pp-080

Injection

Dossier type
EU CTD
Dossier status
Under development
Country of origin
United States
Comments
Indication: Serious infections caused by multidrug-resistant Gram-positive pathogens. Clinical stage: Global multicenter Phase III clinical development following sequential-therapy evaluation; U.S. Phase 2 completed/ China Phase 3 completed. Modality: Small-molecule antibacterial (injectable oxazolidinone). Mechanism / Target: Inhibition of bacterial protein synthesis via binding to the 50S ribosomal subunit, consistent with oxazolidinone pharmacology. Route / form: Injectable formulation, with sequential oral therapy evaluated. Differentiation: Next-generation oxazolidinone engineered to target highly drug-resistant Gram-positive organisms; supported by a national strategic innovation program; QIDP and FDA Fast Track designations underscore its potential to address urgent clinical needs.
Manufacturer #23854

A global biopharmaceutical company developing innovative antibiotics to treat drug-resistant bacterial infections. It advances multiple clinical programs targeting multidrug-resistant pathogens and unmet infectious-disease needs with strategic global development efforts. The organization emphasizes safe, effective next-generation therapies.
 

Want to see all products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

Interested in Subscription?

Please fill out form and send us your specific requirements, and we will get back to you as soon as possible

Want unlimited access to the Pipelinepharma database?

Become a subscriber to unlock:

  • Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.

  • Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.

  • Higher profitability: compare multiple supplier offers and secure the best commercial terms.

  • Expanded network: view supplier portfolios and stay updated on new products.

  • Value-added product ideas: discover products with lower competition potential.

  • Access to marketing authorizations for sale: find already registered products in your target markets.